EHA 2021 Hematologia
Held on 10-13 June, EHA 2021 virtual congress
provided new insights from the world of hematology. We at BestPractice Nordic had an op-
portunity to meet virtually some of the leading scientists within hematology, who presented research findings at EHA.
Dr. Agoston Gyula Szabo of our Scientific Ad-
visory Board put forward questions regarding each study from the Nordic perspective. See
the highlights below and hear the answers on bpno.no.
Data from the MonumentTAL-1 study
Dr. Amrita Y. Krishnan presented an update on
phase I data from the MonumentTAL-1 study on the safety, tolerability and efficacy of the re-
commended phase II dose (RP2D) of talqueta mab in patients with relapsed and refractory multiple myeloma.
Talquetamab is a first-in-class bispecific
immunoglobulin G4 antibody that binds to
CD3 and GPRC5D to activate T cells to attack multiple myeloma cells. The study has shown a
high clinical response rate in patients with relapsed and refractory multiple myeloma.
In our MEDtalk Dr. Krishnan answers the following questions:
• T he response rates reported here are very impressive. Do you think responses will be durable? What is your impression?
• I s there any aspect of talquetamab treatment that is problematic for patients? Any significant hair or nail issues?
• I f you could choose, where would you posi-
tion talquetamab in the sequence of myeloma treatments for your patient?
Dr. Amrita Y. Krishnan, Director of Judy and Bernard Briskin Multiple Myeloma Center, Professor of Hemato logy/Hematopoietic Cell Transplantation, City of Hope Cancer Center
24
BestPractice Nordic / FI / Hematologia / NR. 8 / 2021
